W. Bradford Smith - 14 May 2025 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for W. Bradford Smith
Issuer symbol
LYRA
Transactions as of
14 May 2025
Net transactions value
$0
Form type
4
Filing time
16 May 2025, 16:30:30 UTC
Previous filing
14 Jun 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith W Bradford Director C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN /s/ Jason Cavalier, Attorney-in-Fact for W. Bradford Smith 16 May 2025 0001317678

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Restricted Stock Units Award $0 +32,000 $0.000000 32,000 14 May 2025 Common Stock 32,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.